Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Non Operating Investment Income (2022 - 2025)

Cytek Biosciences (CTKB) has disclosed Non Operating Investment Income for 4 consecutive years, with $38000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Investment Income rose 180.85% year-over-year to $38000.0, compared with a TTM value of $58000.0 through Dec 2025, down 40.21%, and an annual FY2025 reading of $58000.0, down 40.21% over the prior year.
  • Non Operating Investment Income was $38000.0 for Q4 2025 at Cytek Biosciences, down from $118000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $195000.0 in Q3 2024 and bottomed at -$192000.0 in Q2 2023.
  • Average Non Operating Investment Income over 4 years is $11000.0, with a median of -$3000.0 recorded in 2023.
  • Peak annual rise in Non Operating Investment Income hit 1292.86% in 2024, while the deepest fall reached 1466.67% in 2024.
  • Year by year, Non Operating Investment Income stood at $17000.0 in 2022, then crashed by 117.65% to -$3000.0 in 2023, then tumbled by 1466.67% to -$47000.0 in 2024, then surged by 180.85% to $38000.0 in 2025.
  • Business Quant data shows Non Operating Investment Income for CTKB at $38000.0 in Q4 2025, $118000.0 in Q3 2025, and -$33000.0 in Q2 2025.